|
Sign In to gain access to subscriptions and/or personal tools.
|
 |
Click on image to view larger version.

Figure 3. Inhibition of voltage-gated K+ currents by eugenol does not require TRPV1 activation. (A) Capsazepine (CZP) did not block the inhibition of voltage-gated K+ currents by eugenol in rat trigeminal ganglion (TG) neurons. The representative traces of voltage-gated K+ currents under control, CZP (10 µM), and the combined application of eugenol and CZP (left). The inhibition of voltage-gated K+ currents by the combined application of eugenol and CZP was not significantly different from that of eugenol only (mean ± SEM, p > 0.05) (right), indicating that eugenol-induced voltage-gated K+ current inhibition was TRPV1-independent. The number in parentheses represents the number of cells studied. (B) Representative current traces under control and 1 mM eugenol in Ltk– cells (left). Eugenol inhibited hKv1.5 currents in Ltk– cells. The summary of K+ current inhibition in trigeminal ganglion neurons and Ltk– cells (right). The K+ current inhibition by eugenol in trigeminal ganglion neurons was significantly greater than that in Ltk– cells (mean ± SEM, p < 0.05). (Insert) RT-PCR analysis shows no endogenous expression of TRPV1 in Ltk– cells. TRPV1 is clearly expressed in trigeminal ganglion neurons. The expected sizes of PCR products were 233 bp (TRPV1) and 293 bp (β-actin). No PCR products were detected with H2O (lane –).
J DENT RES, Vol. 86, No. 9,
898-902 (2007)
DOI: 10.1177/154405910708600918
|
|